Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa

Inclusion Criteria: * Patients with end stage renal disease (stage CKD 5d), receiving stable subcutaneous maintenance therapy with Epogen® or Procrit® at least once per week * Mean hemoglobin level between 9.0 - 11.5 g/dL during the screening period * Adequate iron substitution Exclusion Criteria: * Contraindications for Erythropoiesis Stimulating Agent (ESA) therapy * History of Pure Red Cell Aplasia (PRCA), or anti-erythropoietin (EPO) antibodies * Known Human Immunodeficiency Virus (HIV) or Hepatitis B infection * Hepatitis C infection on an active treatment * Symptomatic congestive heart failure (New York Heart Association \[NYHA\] class III and IV) * Unstable angina pectoris, or cardiac infarction during the last 6 months prior to randomization * Percutaneous coronary intervention, or coronary artery bypass grafting during the last 6 months prior to randomization * History of malignancy of any organ system * Systemic lupus erythematous * Immunocompromized patients Other In-/Exclusion criteria may apply